|
How to give methotrexate injection |
|
Drugs such as methotrexate or mifepristone are used followed with prostaglandin and misoprostol if in the united states or gemeprost if in the united kingdom or sweden.
W. Rosse, S. Hall, T. Kamitani, and E. T. H. Yeh, unpublished observations. l1 Most of the analyses shown in this report were carried out on [3H]mannose-labeledglycolipids to facilitate the comparison between charged and neutral GPIs and to follow the end products after HF and a-mannosidase treatments. It is not possible to purify [3H] ethanolamine-labeled GPIs M . from TLC plates due to other non13 GPI glycolipids whichmigrated a t the same area. Thus, theinference that all of the charged GPIs contain ethanolamine phosphate was drawn from the Bio-Gel P4 analysis shown in Fig. 1B and by the observations that both [3H]ethanolamine and [3H]mannose-labeled headgroups under peak I-IV have identical RF in a high resolution TLC data not shown ; . Furthermore, HF sensitivity and Mono Q analysis also lend weight to thisinference!
Response Cost QALY Result In your analysis, you state that infliximab is The analysis compares two treatment marginally more beneficial than methotrexate strategies: alone, and quote a QALY cost of 6, 000 1. patients receive infliximab plus per QALY. However, you seem to claim a methotrexate for 14 weeks, after which benefit of 3.63 in Methotrexate patients, 40% of patients switch to methotrexate compared to 3.85 for Infliximab patients. This alone due to inadequate efficacy, and to me seems to contradict the premise that you 5% of patients switch every 6 months are looking at patients in whom MTX has thereafter. been trialled and failed or not tolerated - 2. patients receive methotrexate alone. surely the benefit in these patients must be 0 As large percent of patients who are or close to 0? initiated on infliximab treatment switch to methotrexate alone, the benefits of infliximab plus methotrexate compared with methotrexate alone are not too high. Also note that the average age of patients is 51, therefore the death rate is fairly high. Issue.
11. Mahoney DH Jr, Shuster J, Nitschke R, et al: Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group phase III trial. J Clin Oncol 16: 246-254, 1998 Pullen J, Boyett J, Shuster J, et al: Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 11: 839-849, 1993 Lauer SJ, Shuster JJ, Mahoney DH Jr, et al: A comparison of early intensive methotrexate mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group phase III randomized trial. Leukemia 15: 1038-1045, 2001 Asselin B, Shuster J, Amylon M, et al: Improved event-free survival EFS ; with high dose methotrexate 9HDM ; in T-cell lymphoblastic leuekmia 9T-ALL ; and advanced lymphoblastic lymphoma T-NHL ; : A Pediatric Oncology Group POG ; study. Proc Soc Clin Oncol 20: 367a, 2001 abstr 1464 ; 15. Gelber RD, Sallan SE, Cohen HJ, et al: Central nervous system treatment in childhood acute lymphoblastic leukemia: Long-term follow-up of patients diagnosed between 1973 and 1985. Cancer 72: 261-270, 1993 Land VJ, Thomas PR, Boyett JM, et al: Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia: A Pediatric Oncology Group study. Cancer 56: 81-87, 1985 Ribeiro RC, Rivera GK, Hudson M, et al: An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 13: 333-338, 1995 Neale GA, Pui CH, Mahmoud HH, et al: Molecular evidence for minimal residual bone marrow disease in children with `isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia. Leukemia 8: 768-775, 1994 Goulden N, Langlands K, Steward C, et al: PCR assessment of bone marrow status in `isolated'.
Methotrexate side effects weight gain
Serum methotrexate levels may also be helpful
5. Calin A, Dijkamans BAC, Emery P, et al. Outcomes of a multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-1600. Davis JC, van der Heijde D, Braun J, et al. Recombinant Human Tumour Necrosis Factor Receptor Etanercept ; for Treating Ankylosing Spondylitis. Arthritis Rheum 2003; 48 11 ; : 3230-3236. 7. Davis JC, van der Heijde D, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005; 64: 1557-1562 Engelmann H, Holtmann H, Brakebusch, et al. Antibodies to a soluble form of a tumour necrosis factor TNF ; receptor have TNF-like activity. J Biol Chem 1990; 265: 14497. Feldmann M, Brennan FM, Maini RN. The role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996; 14: 397. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 6: 727. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002; 46: 1443-1450. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthr Rheum 1997; 40 7 ; : 1202. 13. Gladman D, Rahman P. Psoriatic Arthritis. In: Kelley's Textbook of Rheumatology Sixth Edition. 2001; 71: 1071-1079. Gladman D. Effectiveness of Psoriatic Arthritis Therapies. Seminars in Arthritis and Rheumatism. 2003; 33 1 ; : 29-37. 15. Gorman JD, Sack KE, Davis JCJ. Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor . N Engl J Med 2002; 346 18 ; : 1349-56. 16. Grom A, Murray KF, Luyrink L et al. Patterns of expression of tumour necrosis factor , tumour necrosis factor , and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum 1996; 39: 1703. Klareskog L, van der Heidje D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone and methylcellulose.
Sinkule JA, Hutson PR, Hayes FA, Etcubanas E, Evans WE: Pharmacokinetics of etoposide VP-16 ; in children and adolescents with refractory solid tumors. Cancer Res 1984; 44: 3109-3113. Evans WE, Stewart CF, Hutson PR, Cairnes DA, Bowman WP, Crom WR: Disposition of intermediatedose methotrexate in children with acute lymphocytic leukemia. Drug Intell Clin Pharm 1982; 16: 839842.
| Plasma methotrexate levelArdizzone, 1998; Fiorentino et al., 1998b ; . Consequently, it is expected that the recently applied ban of trawling in European Mediterranean waters at depths of less than 50 m, and the increase of the trawl cod-end mesh size, will favour the recruitment of Mullus species. Areas of recruitment could not be traced from the presently collected data, as the surveys were accomplished depending on the area and year ; within or just after the reproductive period, occurring from May to July for M. barbatus Larraeta and Rodrguez Roda, 1956; Livadas, 1988; Vrantzas et al., 1992; Tursi et al., 1994 ; and April to June for M. surmuletus Morales-Nin, 1991; Vassilopoulou and Papaconstantinou, 1992b ; . Consequently, recruitment was not generally evident, apart from certain years, in eastern Mediterranean areas. REFERENCES and methyldopa.
Methotrexate rash pictures
In 1959 we introduced the concept of prolonged con tinuous ; i.v. and intra-arterial infusion of cancer chemo therapeutic compounds and reported the profound altera tions of the biologic effects of several of these compounds in terms of dose-toxicity response and anti-tumor effects that result from these methods of administration. We have previously reported the rationale for prolonged ther apy and clinical studies of the effects of the continuous infusion of methotrexate 14, 17 ; , 5-fluorouracil 5-FU ; and 5-FUDR 15, 19, ; , mitomycin C 10 ; , and strep tonigrmn 18 ; . The current report, representing one of a series of such studies, describes an evaluation of the anti tumor effects of 5-FUDR in human cancer when this agent.
A. Cytotoxicity of antifolates to DG44 cells transfected with wt and mutant variants of DHFR IC50 Methotrexate Pemetrexed and methysergide
| Methotrexate side effects methotrexate commonly causes nausea and vomiting.
Pean Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 2000; 18: 26482657. Cascinu S, Labianca R, Alessandroni P et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epidoxorubicin, 6s-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997; 15: 33133310. Cervantes A, Villar-Grimalt A, Abad A et al. 5-Fluorouracil, folinic acid, epidoxorucin and cisplatin FLEP ; combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy TTD ; . Ann Oncol 1993; 4: 753757. Massuti B, Cervantes A, Aranda E et al. A phase II multicentric randomized trial in advanced gastric cancer GC ; : fluorouracil + leucovorin + epirubicin + cisplatin FLEP ; vs fluorouracil + adriamycin + methotrexate + leucovorin FAMTX ; : response and survival report. Proceedings of the Sixth International Congress on Anti-cancer Treatment, Paris, France, February 69, 1996. Paris, Service d'Oncologic Mfical, Hospital PitiSalpetrire 1996; 120 Abstr UI: 97614417 ; . Findlay M, Cunningham D, Norman A et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil ELF ; . Ann Oncol 1994; 5: 609 Zaniboni A, Barni S, Labianca R et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer GISCAD ; report. Cancer 1995; 76: 16941699. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261267. Waters JS, Norman A, Cunningham D et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomised trial. Br J Cancer 1999; 80: 269272. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous infusion of fluorouracil PVI 5-FU ; with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20; 19962004. Hasham-Jiwa N, Kasakura Y, Ajani JA. Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 19952001. Int J Clin Oncol 2002; 7: 219224. Kim YH, Shin SW, Kim BS et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85: 295301. Roth AD, Maibach R, Martinelli G et al. Docetaxel Taxotere ; cisplatin TC ; : an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research SAKK ; , and the European Institute of Oncology EIO ; . Ann Oncol 2000; 11: 301306. Pozzo C, Bugat R, Peschel C et al. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastrooesophageal junction adenocarcinoma: final results of a randomised phase II study. Proc Soc Clin Oncol 2001; 20: 134a Abstr 531 ; . 19. Artru P, Andr T, Tigaud JM et al. Oxaliplatin OXA ; , 5-fluoro-uracil FU ; and folinic acid FA ; FOLFOX 6 ; in advanced metastatic gastric carcinoma A MGC ; patients Pts ; : final results of a multicenter phase II study. Proc Soc Clin Oncol 2001; 20: 164a Abstr 654 and metolazone.
Methotrexate for arthritis in children
In the weaning of patients with trustee, caution must be exercised if high-dose methotrexate is administered in herbicide with a additionally nuts depressing bishop eg, cisplatin.
Blood-to-blood contact, e.g. sharing needles. Sexual transmission is uncommon. Mother to child transmission is possible and micafungin.
Additionally, preliminary reports of randomized, controlled trials of methotrexate therapy of pbc in europe noted a higher than expected rate of a form of pneumonia that scars the lungs.
A. Intravenous IV ; prostacyclin analogue; b. Subcutaneous or IV prostacyclin analogue, oral and inhaled formulations are undergoing randomised trials; c. Non-selective endothelin receptor antagonist; d. Phosphodiesterase PDE ; -5 inhibitor; e. Inhaled prostacyclin analogue; f. Not US Food and Drug Administration FDA ; -approved for this purpose; g. Primarily used in a hospital setting and as a vasoreactivity testing agent; h. Endothelin A ETA ; receptor selective antagonist, randomised studies completed; i. PDE5 inhibitor; randomised studies in progress; j. Oral prostacyclin analogue, available outside the US, FDA approval not sought after randomised study results; k. Rho-kinase inhibitor; l. Tyrosine kinase inhibitor, feasibility studies under way in Europe; m. Commonly used and felt to be efficacious in reducing symptoms or consequences, but no rigorous study data. Adapted from McGoon. PAH pulmonary arterial hypertension; FDA US Food and Drug Administration; ACE angiotensin-converting enzyme and midodrine.
Evaluate the processing of insulin in Fao cells, the dissociation of internalized insulin from its receptor inside the cell was directly studied by measuring the polyethylene glycol precipitability of intracellular `251-insulin. Intracellular insulin was initially X30% polyethylene glycol-precipitable, suggesting that most of the insulin was receptor-bound immediately after internalization. After 1 min, the polyethylene glycol precipitability of the internalized insulin decreased rapidly, with ~20% of the internalized insulin bound to receptor after 7.5 min Fig. 3 ; . The intracellular dissociation of insulin appeared first-order on a semilogarithmic plot, with tlh 3 min data not shown ; . To compare the kinetics of the intracellular dissociation and degradation, the trichloroacetic acid precipitability of the internalized insulin was measured Fig. 3 ; . Intracellular insulin was initially 90% trichloroacetic acid-precipitable, suggesting that little if any degradation occurred prior to internalization. However, after 1 min, the trichloroacetic acid precipitability of the internalized insulin fell rapidly, with TL12 3 min data not shown ; . Thus, the half-times for intracellular insulin dissociation and degradation at 37 "C were the same and methotrexate.
Methotrexate hair loss low dose
Vaccination, or the deliberate induction of protective immunity by administering nonpathogenic forms of a microbe or its antigens to induce a memory immune response, is the world's most cost-effective medical procedure for preventing morbidity and mortality caused by infectious disease1 . Historically, most vaccines have worked by eliciting long-lived plasma cells. These cells produce antibodies that limit disease by neutralizing a toxin or blocking the spread of the infectious agent. For these `B cell vaccines, ' the immunological marker, or correlate, for protection is the titer of protective antibodies. With the discovery of HIV AIDS, vaccine development has been confronted by an agent that is not easily blocked by antibody2. To overcome this, researchers who are developing HIV AIDS vaccines have turned to the elicitation of cellular immunity, or `T cell vaccines, ' which recognize and kill infected cells3, 4 and mifeprex.
Drug Dose and Target Cyclophosphamide 800 mg m2 IV day 1, then 200 mg m2 d IV days 2-5 Vincristine 1.5 mg m2 IV days 1, 8 in cycle 1 and on days 1, 8, and 15 on cycle 3 Doxorubicin 40 mg m2 IV day 1 Cytarabine intrathecal 70 mg days 1, 3 Methotrexate 1200 mg m2 IV over 1 hour, followed by 240 mg m2 hour for the next 23 hours starting on day 10 Calcium leucovorin 192 mg m2 IV to start 12 hours after the completion of the methotrexate infusion x 1 dose, then 12 mg m2 IV every 6 hours until the methotrexate level is 5x10-8 mol L GM-CSF 7.5 mcg kg d subcutaneously day 13 onwards until ANC 1000. Methotrexate 12 mg intrathecal IT ; day 15 Notes: Patients with CNS disease at presentation received additional intrathecal therapy during the first CODOXM cycle with IT cytarabine day 5 and IT MTX day 17 Regimen consists of alternating cycles of CODOXM and IVAC for a total of 4 cycles.
30 penalties. In the Table 4 examples, the EDR score is 31.3%. It is computed as follows, using ACE parameters from 20046. Each of the five entities contributes up to a maximum value to the final score. Using default ACE parameters, the maximum values MAXVAL ; for person entities is 61.54% of the final score, the two organizations worth 30.77%, and the location worth 7.69%. These values sum up to 100%. At the individual type level, one person span was recognized John Briggs Jr ; but with the wrong type organization one person entity was missed Robert the two organization spans Wonderful Stockbrockers Inc and Acme ; were considered correct, even with the former partial matches; one geopolitical span was recognized in New York ; but with the wrong type; and there was one false alarm On ; . Globally, the person entities error function of COST and MAXVAL ; accounts for 55.31% of the final EDR loss 30.77 for the miss and 24.54 for the type error ; , the false alarm account for 5.77% of loss, and the location type error accounts for 7.58%. The final EDR of 31.3% is 100% minus these losses and mifepristone.
Methotrexate subcutaneous arthritis
Arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum. 2006; 54: 702-710. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 1999; 42: 1854-1860. Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patients and trial profiles. J Rheumatol. 1993; 20: 561-565. van der Heijde DM, Van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis. 1992; 51: 177-181. Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum. 2005; 52: 2625-2636. Aletaha D, Machold K, Nell VPK, Smolen JS. Rheumatoid arthritis core set measures and perception by rheumatologists. Arthritis Rheum. 2005; 52 Suppl ; . 17. Molenaar ET, Voskuyl AE, Dijkmans BA. Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission. J Rheumatol. 2002 Feb; 29 2 ; : 267-270. 18. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981; 24 10 ; : 1308-1315. 19. Prevoo ML, van Gestel AM, van THM, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996 Nov; 35 11 ; : 1101-1105. 20. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology. 2007 in press ; . 21. Food and Drug Administration. Clinical development programs for drugs, devices and biological products for the treatment of rheumatoid arthritis. US Department of Health and Human Services, Feb 1999. Available at fda.gov cber gdlns rheumcln . Last accessed February 21, 2007. 22. Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol. 2006; 24 6 Suppl 43 ; : S045-S051. 23. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis. 2005; 64: 1410-1413. Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol. 2006; 24 6 Suppl 43 ; : S007-S013. 25. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis. 2005; 64: 1582-1587. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study--A multicenter, randomized, doubleblind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54: 26-37. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006 Aug 31; 54 9 ; : 28172829. 28. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum. 2004; 50: 3432-4343. Mierau M, Gonda G, Pezawas L, et al. Defining remission in rheumatoid arthritis using different instruments. Arthritis Rheum. 2005; 52 Suppl ; : 239. 30. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol. 1991; 18: 1298-1306. Heiberg T, Kvien TK. Preferences for improved health examined in 1, 024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum. 2002 Aug; 47 4 ; : 391397. 32. Antoni CE, Maini R, Grunke M, Gefeller O, Stalgis C, Smolen J, et al. Cooperative on quality of life in rheumatic diseases: results of a survey among 6000 patients across 11 European countries. Arthritis Rheum. 2002; 46 Suppl 1 ; : Abstract 98. 33. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis the BeSt study ; : A randomized, controlled trial. Arthritis Rheum. 2005; 52: 3381-3390. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis the TICORA study ; : a single-blind randomized controlled trial. Lancet. 2004; 364: 263-269 and methylcellulose.
Methotrexate psoriasis pictures
Methotrexate 15mg
Blindness video, mantoux test , avery high school, bifidus and group a strep azithromycin. Intrinsic disease, demyelination disease, phimosis yahoo and doxycycline brand name or abstinence groups.
Methotrexate 2.5mg tablet myl
Meethotrexate, methotrexatee, methotrexte, jethotrexate, methotrexare, mtehotrexate, methotrexae, methot5exate, m3thotrexate, methotrexatd, mwthotrexate, methotrexaye, methotdexate, metnotrexate, metthotrexate, methoterxate, methltrexate, methotresate, mfthotrexate, emthotrexate.
Methotrexate gestational trophoblastic disease
Methotrexate hepatitis c, methotrexate side effects weight gain, plasma methotrexate level, methotrexate rash pictures and methotrexate for arthritis in children. Methotrexate hair loss low dose, methotrexate subcutaneous arthritis, methotrexate psoriasis pictures and methotrexate 15mg or methotrexate 2.5mg tablet myl.
|
